Search
Recent findings by Memorial Sloan Kettering investigators suggest it might be possible to improve the effectiveness of chemotherapy for breast cancer by combining the treatment with a new type of drug called a cathepsin inhibitor.
Deb Schrag, MD, MPH, FASCO, gastrointestinal medical oncologist and George J. Bosl Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK), has been elected 2027-28 President of the American Society of Clinical Oncology (ASCO), the world's leading professional organization for physicians and oncology professionals caring for people with cancer.
Researchers from MSK presented findings on graft-versus-host disease and other topics at the annual meeting of bone marrow transplant and cellular therapy experts.
Memorial Sloan Kettering’s suburban presence is expanding with its newest and largest state-of-the-art facility set to welcome patients on October 6 in West Harrison, New York.
Experiments with zebrafish and human pluripotent stem cells reveal the necessary ingredients, besides genetic mutations, that fuel the development of melanoma.
Justin Perry, PhD, cell biologist and immunologist of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named a recipient of the 2021 National Institutes of Health (NIH) Director’s New Innovator Award.
Learn how multiple myeloma prognosis has improved significantly with the emergence of new drug treatments.
Gerstner Sloan Kettering held its inaugural retreat, on April 30 and May 1, to foster scientific and personal exchanges between students and faculty.